Ülke: Kanada
Dil: İngilizce
Kaynak: Health Canada
TIOTROPIUM (TIOTROPIUM BROMIDE MONOHYDRATE)
BOEHRINGER INGELHEIM (CANADA) LTD LTEE
R03BB04
TIOTROPIUM BROMIDE
2.5MCG
SOLUTION
TIOTROPIUM (TIOTROPIUM BROMIDE MONOHYDRATE) 2.5MCG
INHALATION
4ML(60 PUFFS OR 28 PUFFS)
Prescription
ANTIMUSCARINICS ANTISPASMODICS
Active ingredient group (AIG) number: 0148683002; AHFS:
APPROVED
2014-12-17
_Spiriva_ _®_ _ Respimat_ _®_ _ Product Monograph Page 1 of 41_ PRODUCT MONOGRAPH Pr SPIRIVA ® RESPIMAT ® Tiotropium (as tiotropium bromide monohydrate) Inhalation Solution 2.5 mcg per actuation Bronchodilator Long-Acting Muscarinic Antagonist (LAMA) SPIRIVA ® RESPIMAT ® cartridge for use only with the SPIRIVA ® RESPIMAT ® Inhaler Boehringer Ingelheim (Canada) Ltd. 5180 South Service Road Burlington, Ontario. L7L 5H4 Date of Revision: May 7, 2019 Submission Control No: 224205 BICL # 0269-10 Spiriva ® and Respimat ® are registered trademarks of Boehringer Ingelheim International GmbH, used under license. _Spiriva_ _®_ _ Respimat_ _®_ _ Product Monograph Page 2 of 41_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ..........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ....................................................................................................7 DRUG INTERACTIONS ..................................................................................................11 DOSAGE AND ADMINISTRATION ..............................................................................12 OVERDOSAGE ................................................................................................................13 ACTION AND CLINICAL PHARMACOLOGY ............................................................14 STORAGE AND STABILITY ..........................................................................................18 SPECIAL HANDLING INSTRUCTIONS .......................................................................18 DOSAGE FORMS, COM Belgenin tamamını okuyun